National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Kidney Cancer

Kidney cancer is a disease that occurs when malignant (cancer) cells form in tissues of the kidneys. There are several types of cancer that can start in the kidney:

  • Renal cell cancer: Found in the lining of tubules (very small tubes) in the kidney and is the most common type of kidney cancer in adults
  • Tansitional cell carcinoma: Affects the renal pelvis and is similar to and often treated like bladder cancer
  • Wilms tumor: The most common type of childhood kidney cancer

People with von Hippel-Lindau syndrome (VHL), Birt-Hogg-Dubé syndrome; hereditary papillary renal cell carcinoma; and hereditary leiomyomatosis and renal cell cancer (HLRCC) have a much higher risk for being diagnosed with kidney cancer.

In advanced cases, kidney cancer cells may invade surrounding tissues or spread (metastasize) to other parts of the body via the blood stream or lymph system.

Excluding non-melanoma cancers of the skin, kidney cancer is the seventh most common type of cancer among men and the ninth most common among women. Men are about two times more likely than women to be diagnosed with kidney cancer.

It is estimated that 65,150* people in the United States will be newly diagnosed with kidney cancer in 2013.

Treatment options for kidney cancer vary depending on the stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Kidney Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with kidney cancer. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Kidney (Renal Cell) Cancer
Phase II
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
NCI-10-C-0114, NCT01130519

Principal Investigator:Referral Contact:
Ramaprasad SrinivasanGeri Hawks
301-496-6353301-402-7913
ghawks@mail.nih.gov
A Phase II Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
NCI-09-C-0057, NCT00820209

Principal Investigator:Referral Contact:
Antonio Tito FojoMaureen Edgerly
301-402-1357301-435-5604
edgerlym@mail.nih.gov
Phase I/II
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells
NCI-08-C-0088, NCT00923845

Principal Investigator:Referral Contact:
Daniel H. FowlerZetta Blacklock
301-435-8641301-594-2056
bblacklock@mail.nih.gov


  
Trial and Protocol Number
Bladder Cancer
Phase II
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
NCI-12-C-0205, NCT01437488

Principal Investigator:Referral Contact:
Andrea B. ApoloLaura D. Otten
301-496-4916301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov


  
Trial and Protocol Number
Leiomyomatosis
No Phase
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
NCI-03-C-0066, NCT00055627

Principal Investigator:Referral Contact:
W. Marston LinehanLindsay A. Middleton
301-496-6353301-402-7911



  
Trial and Protocol Number
Melanoma
Phase I
A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Metastatic Melanoma and Metastatic Renal Cell Cancer
NCI-10-C-0021, NCT01021059

Principal Investigator:Referral Contact:
Thomas WaldmannTat’Yana Worthy
301-496-6656301-496-0499
worthyt@mail.nih.gov


  
Trial and Protocol Number
Pediatric Cancers
Phase II
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
NCI-12-C-0098, NCT01502410

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Solid Tumor
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
NCI-11-C-0013, NCT01218867

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression
NCI-13-C-0016, NCT01730118

Principal Investigator:Referral Contact:
Lauren V. WoodBrenda Roberson
301-402-0199301-435-4733
broberson@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
NCI-09-C-0019, NCT01445509

Principal Investigator:Referral Contact:
Elise C. KohnLaura D. Otten
301-402-2726301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov


  
Trial and Protocol Number
von Hippel-Lindau Syndrome
Phase II
A Phase II Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors
NCI-08-C-0020, NCT00566995

Principal Investigator:Referral Contact:
W. Marston LinehanSarah Fowler
301-496-6353301-435-6255
fowlers@mail.nih.gov
No Phase
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders
NCI-89-C-0086, NCT00019617

Principal Investigator:Referral Contact:
W. Marston Linehan
301-496-6353



Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov